Inquiry
Accelerated & Innovative
Therapeutic Antibody Discovery
WIN Your Therapeutic Antibody Program at the Start Line
Camelid Nanobody Development
Nanobodies are a type of antibody fragment that are smaller in size compared to traditional antibodies. They are derived from heavy-chain antibodies found in camelids (alpaca and llama etc.) and other animals, and their compact size makes them particularly useful in applications where size is a limiting factor, such as imaging, drug delivery, and therapeutic applications. Combining our SMab™ platform with phase display technology coupled with large scale screening has enabled Yurogen to develop nanobodies with great diversity, specificity, and affinity with short turnaround time.
Service Features
Dual Platform

Proprietary Smab platform plus phage display platform used to improve diversity

Proprietary Algorithm

NGS sequencing combined with proprietary algorithm to dig out rare VHH sequence

Unique Immunization

Expertise in DNA Immunization and cell membrane extract immunization

Multiple Expression Host

Choice of E.Coli, Pichia pastoris, and mammalian expression system

Reliable Animal Source

USDA certified animal farm & guaranteed naive llamas without immune background

Professional Support Team

PhD. level scientists provide tailored technical support & customer service

Procedure
  • Phase I: Immunization
  • Phase II: : SMab™ or phage display platform Screening for VHH
  • Phase III: VHH expression and purification
Workflow
PlatformPhaseServiceDescriptionTimeline
Phase IImmunization

  • Standard Package: Immunize ONE llama or alpaca for 6-9 weeks with 4 injections and 3 bleed collections
  • Bleed titer and blocking measured with ELISA for IgG2/3 and total IgG
  • (Optional) Additional Assays: counter screen ELISA & FACS etc.
  • PBMC isolation
  • Phase I report

6-9 weeks
SMab™ PlatformPhase IIaLlama Single B cell Sorting

  • Antigen and IgG2/3 double specific llama B cell sorting & culture
  • High throughput ELISA screening for cultured supernatant
  • Freeze the cell pallet for selected ELISA positive clones
  • Further function assay for the supernatant of positive clones

2 weeks
Phase IIbVHH cloning & LEM Construction

  • Amplification of VHH genes from selected positive clones
  • Construction of Linear Expression Module (LEM) (Optional)
  • HEK293 cells transfected with LEM for recombinant expression and further functional assay (Optional)

2-3 weeks
Phage Display PlatformPhase IIaPhage Display Library Construction

  • VHH phage display library construction
  • VHH phage display library QC, including
  • The diversity of library: > 108 cfu
  • The size of library: > 1011 cfu
  • VHH insert rate: > 95%

4 weeks
Phase IIbLibrary Screen & Sequencing of positive clone

  • Enrichment of antigen-specific phages (2 or 3 cycles)
  • Pick up to 4 X 96 binders for further phage ELISA primary and secondary screening
  • Sanger sequencing of ELISA positive phages for VHH gene
  • Perform next-generation sequencing (NGS) for all enriched phages; positive candidates recommendation with Proprietary unique Algorithm (optional)

4 weeks